115TiP Stereotactic body radiotherapy (SBRT) plus anlotinib with or without toripalimab in driver mutation-negative non-small cell lung cancer (NSCLC) patients with untreated brain oligometastatic metastases: A prospective, single-center, phase Ib study

SBRT is a treatment modality for intracranial lesions of oligometastatic NSCLC. Combined with immune checkpoint inhibitors (ICIs), SBRT can improve the anti-tumor effect and the systemic response to immunotherapy via the abscopal effect in brain metastases (BMs) NSCLC patients. Meanwhile, the combination of anlotinib（a novel multi-target tyrosine kinase inhibitor）and ICIs can promote the infiltration of the innate immune cells and conferred potentially synergistic anti-tumor activity. Therefore, triple therapy of SBRT, anlotinib, and toripalimab (anti-PD-1 antibody) may be more effective in driver mutation-negative NSCLC patients with untreated oligometastatic BMs.